VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need. The company holds exclusive worldwide rights to research, develop, and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for any disease in humans, licensed from Tay Therapeutics Ltd. VYNE's core activities involve advancing its pipeline of BET inhibitors, including repibresib gel (VYN201), a topical pan-BD BET inhibitor, and VYN202, an oral BD2-selective BET inhibitor, through preclinical and clinical development stages.

VYNE Therapeutics Inc. generates revenue primarily through potential future commercialization of its product candidates, as it currently has no marketed products or recurring revenue streams. The company's business model relies on advancing its BET inhibitor platform through clinical trials, with the intention of monetizing its assets via partnerships, licensing, or outright sales of its intellectual property and product candidates such as repibresib gel and VYN202.

The company operates through the following segments:

• Repibresib Program: This segment focuses on the development and commercialization of repibresib gel (VYN201), a topically administered, small molecule pan-BD BET inhibitor designed as a soft drug to address diseases involving multiple inflammatory cell signaling pathways while providing low systemic exposure. The company initiated a Phase 2b trial in nonsegmental vitiligo in June 2024, which did not meet its primary endpoint in July 2025, leading to trial termination. Repibresib gel is covered by patents providing composition of matter exclusivity into at least 2042 in the United States and 2040 in Europe, Japan, and other major markets.

• VYN202 Program: This segment centers on VYN202, an oral, small molecule BD2-selective BET inhibitor designed to achieve class-leading potency and selectivity for BD2 over BD1. By maximizing BD2 selectivity, VYN202 aims to serve as a potent oral immunomodulator for immune-mediated conditions without the hematologic and gastrointestinal adverse effects associated with earlier pan-BD BET inhibitors. VYNE initiated a Phase 1b trial in moderate-to-severe plaque psoriasis in February 2025, which encountered a clinical hold due to testicular toxicity in dogs; the hold was partially lifted for female subjects in June 2025, and a repeat toxicology study in male dogs was initiated in October 2025, expected to complete in the second half of 2026.

VYNE Therapeutics Inc. operates in a highly competitive biopharmaceutical landscape, facing intense rivalry from large pharmaceutical companies such as AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, UCB, LEO Pharma, Janssen Pharmaceuticals, Roche, Eli Lilly, and Pfizer, which have approved or are developing small molecule and biologic therapies for immune-mediated conditions like psoriasis. The company's competitive advantage lies in its exclusive global rights to Tay Therapeutics' BET inhibitor library and its focus on BD2-selective inhibition, which may offer a differentiated mechanism to modulate the NF-kB pathway without the broad immunosuppressive effects of corticosteroids.

VYNE Therapeutics Inc. serves patients suffering from immune-mediated inflammatory diseases, with current clinical focus on conditions such as nonsegmental vitiligo and plaque psoriasis. The company's product candidates are intended for individuals with moderate-to-severe forms of these conditions who have not responded adequately to existing therapies, targeting populations in dermatology and rheumatology care settings.